LY 307853
Latest Information Update: 22 May 1997
At a glance
- Originator Eli Lilly and Company
 - Class Antifungals; Antiprotozoals
 - Mechanism of Action Glucan synthase inhibitors
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity No
 
Highest Development Phases
- Discontinued Mycoses
 
Most Recent Events
- 01 May 1997 New profile
 - 01 May 1997 Discontinued-Preclinical for Mycoses in USA (IV)